Kidney transplantation and hyperparathyroidism
https://doi.org/10.23873/2074-0506-2017-9-2-137-152
Abstract
Successful kidney transplantation eliminates endocrine and metabolic disorders that predispose to the development of hyperparathyroidism, the complication typical for the chronic kidney disease; but the process of recovery from mineral and bone disorders is slowed down. The highest incidence of post-transplant hyperparathyroidism is recorded in the first postoperative year. The risk factors for its development or persistence include the high blood levels of parathyroid hormone, calcium, phosphorus, and/or alkaline phosphatase, a prolonged dialysis therapy, severe hyperparathyroidism in the preoperative period, vitamin D deficiency, a suboptimal transplanted kidney function, and also the recipient's previous history of subtotal or incomplete parathyroidectomy. The characteristic clinical and laboratory signs of posttransplant hyperparathyroidism are bone lesions, kidney graft abnormalities, hypercalcemia, and hypophosphatemia. The diagnostic algorithm includes monitoring the markers of mineral and bone metabolism, determining the bone mineral density, and imaging of thyroid glands. Correction of post-transplant hyperparathyroidism is performed surgically or pharmacologically. The article specifies the indications to, the extent and timing of parathyroidectomy, discusses the use of native vitamin D formulations, its analogues, and calcimimetics.
About the Author
O. N. Vetchinnikova
Moscow Regional Research and Clinical Institute n.a. M.F. Vladimirskiy
Russian Federation
Russian Federation
Dr. Med. Sci., Senior Researcher of Surgical Department of Transplantation and Dialysis at Moscow Regional Research and Clinical Institute n.a. M.F. Vladimirskiy
References
1. Cunningham J., Locatelli F., Rodriguez M. Secondary Hyperparathyroidism: Pathogenesis, Disease Progression and Therapeutic Options. Clin J Am Soc Nephrol. 2011;6(4):913– 921. PMID:21454719 DOI:10.2215/CJN.06040710
2. Jamal S.A., Miller P.D. Secondary and Tertiary Hyperparathyroidism. J Clin Densitometry: Assessment of Skeletal Health. 2013;16(1):64–68. PMID:2326774 DOI:101016/j.jocd.2012.11.012
3. Evenepoel P. Recovery versus persistence of disordered mineral metabolism in kidney transplant recipients. Semin Nephrol. 2013;33(2):191–203. PMID:23465505 DOI:10.1016/j.semnephrol.2012.12.019
4. Vetchinnikova O.N., Shestero E.V., Egorova E.A. Mineral and bone disorders in renal transplant recipients. Nephrology (Saint-Petersburg). 2016;20(6):49–56. (In Russian). DOI:10.24884/1561-6274-2016-6-49-56
5. Perrin P., Caillard S., Javier R.M., et al. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. Am J Transplant. 2013;13(10):2653–2663. PMID: 24034142 DOI:10.1111/ajt.12425
6. Wolf M., Weir M.R., Kopyt N., et al. Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. Transplantation. 2016;100(1):184– 189. PMID:26177089 DOI:10.1097/TP.0000000000000823
7. Tillmann F.-P., Wächtler C., Hansen A., et al. Vitamin D and cinacalcet administration pre-transplantation predict hypercalcaemic hyperparathyroidism post- transplantation: a case-control study of 355 deceased-donor renal transplant recipients over 3 years. Transplantation Research. 2014;3(3):21–26. PMID:25606342 DOI:10.1186/s13737-014-0021-5
8. Grethen E., Hill K.M., Jones R., et al. Serum leptin, parathyroid hormone, 1,25- dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity. J Clin Endocrinol Metab. 2012;97(5):1655–1662. PMID:22362819 DOI:10.1210/jc.2011-2280
9. Ermolenko V.M., Volgina G.V., Mikhaylova N.A., et al. Treatment of mineral and bone disorders in chronic kidney disease. In: Shilov E.M., Smirnov A.V., Kozlovs kaya N.L., eds. Nephrology. Clinical recommendations. Moscow: GEOTARMedia Publ., 2016. 687–709. (In Russian).
10. Bleskestad I.H., Bergrem H., Leivestad T., et al. Parathyroid hormone and clinical outcome in kidney transplant patients with optimal transplant function. Clin Transplant. 2014;28:479–486.PMID:25649861 DOI:10.1111/ctr12341
11. Evenepoel P., Claes K., Kuypers D., et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: A singlecentre study. Nephrol Dial Transplant. 2004;19(5):1281–1287. PMID:14993493 DOI:10.1093/ndt/gfh128
12. Scillitani A., Guarnieri V., De Geronimo S., et al. Blood ionized calcium is associated with clustered polymorphisms in the carboxyl-terminal tail of the calcium-sensing receptor. J Clin Endocrinol Metab. 2004;89(11):5634–5638. PMID:15531522 DOI:10.1210/jc.2004-0129
13. Weidong W., Chunling L. Reduce expression of renal Na+ transporter in rats with PTH-induced hypercalcemia. Am J Physiol Renal Physiol. 2004;286(3):534–545. PMID:14625199 DOI:10.1152/ajprenal.00044.2003
14. D’Marco L., Bellasi A., Mazzaferro S., Raggi P. Vascular calcification, bone and mineral metabolism after kidney transplantation. World J Transplant. 2015;5(4):222– 230. DOI:10.5500/wjt.v5.i4.222
15. Egbuna O.I., Taylor J.G., Bushinsky D.A., Zand M.S. Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin Transplant. 2007;21(4):558–566. PMID:17645720 DOI:10.1111/j.1399-0012.2007.00690.x
16. Kawarazaki H., Shibagaki Y., Fukumoto S., et al. Natural History of Mineral and Bone Disorders After Living-Donor Kidney Transplantation: A One-Year Prospective Observational Study. Ther Apher Dial. 2011;15(5):481–487. PMID:21974702 DOI:10.1111/j.1744-9987.2011.00932.x
17. Bleskestad I.H., Thorsen I.S., Jonsson G., et al. Soluble Klotho and intact fibroblast growth factor 23 in long-term kidney transplant patients. Eur J Endocrinol. 2015;172(4):343–350. PMID:25572388 DOI:10.1530/EJE-14-0457
18. Tomida K., Hamano T., Ichimaru N., et al. Dialysis vintage and parathyroid hormone level, not fibroblast growth factor- 23, determines chronic-phase phosphate wasting after renal transplantation.Bone. 2012;51(4):729–736. PMID:2796419 DOI:10.1016/j.bone.2012.06.027
19. Hiemstra T.F., Brown A.J., Chaudhry A.N., Walsh M. Association of calcium, phosphate and parathyroid hormone with renal allograft function: a retrospective cohort study. Am J Nephrol. 2013;37(4):339–345. PMID:23548209 DOI:10.1159/000348376
20. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1-S130. PMID:19644521 DOI:10.1038/ki.2009.188
21. Alshayeb H.M., Josephson M.A., Sprague S.M. CKD – Mineral and Bone Disorder Management in Kidney Transplant Recipients. Am J Kidney Dis. 2013;61(2):310–325. PMID:23102732 DOI:10.1053/j.ajkd.2012.07.022
22. Ketteler M., Elder G.J, Evenepoel P., et al. Revisiting KDIGO clinical practice guideline on chronic kidney disease mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int. 2015(3);87:502–528. PMID:25651364 DOI:10.1038/ki.2014.425
23. Naylor K.L., Zou G., Leslie W.D., et al. Frequency of bone mineral density testing in adult kidney transplant recipients from Ontario, Canada: a populationbased cohort study. Canadian Journal of Kidney Health and Disease. 2016;3(3):2–9. PMID:26779343 PMCID:PMC4715326 DOI:10.1186/s40697-016-0092-y
24. Naylor K.L., Jamal S.A., Zou G.Y., et al. Fracture incidence in adult kidney transplant recipients. Transplantation. 2016;100(1):167–175. PMID:26154389 DOI:10.1097/TP.0000000000000808
25. Nishiyama K.K., Pauchard Y., Nikkel L.E., et al. Longitudinal HR-pQCT and Image Registration Detects Endocortical Bone Loss in Kidney Transplantation Patients. Journal of Bone and Mineral Research. 2015;30 (3):554–561. PMID:25213758 DOI:10.1002/jbmr.2358
26. Kalinin A.P., ed. Methods of visualization of parathyroid glands and parathyroid surgery: a guide for physicians. Moscow: Izdatel'skiy dom Vidar-M Publ., 2010. 311 p. (In Russian).
27. Zakharova N.M., Vetchinnikova O.N., Ivantsova L.P. Cytological diagnosis of hyperparathyroidism. Clinical laboratory diagnostics. 2014;59(12):36–40. (In Russian).
28. Zakharova N.M., Vetchinnikova O.N., Ivantsova L.P. Cytomorphological features of parathyroid glands with various forms of hyperparathyroidism. Clinical laboratory diagnostics. 2016;61(10):697– 700. (In Russian).
29. Kievit A.J., Tinnemans J.G.M., Idu M.M., et al. Outcome of Total Parathyroidectomy and Autotransplantation as Treatment of Secondary and Tertiary Hyperparathyroidism in Children and Adults. World J Surg. 2010;34(5):993–1000. PMID:20145928 PMCID:PMC2848726 DOI:10.1007/s00268-010-0446-z
30. Park J.H., Kang S.-W., Jeong J.J., et al. Surgical treatment of tertiary hyperparathyroidism after renal transplantation: A 31-year experience in a single institution. Endocrine Journal. 2011;58(10):827–833. PMID:21804261
31. Lou I., Schneider D.F., Leverson G., et al. Parathyroidectomy is underused in patients with tertiary hyperparathyroidism after renal transplantation. Surgery. 2016;159(1):172–179. PMID:26603850 PMCID:PMC4688142 DOI:10.1016/j.surg.2015.08.039
32. Ferreira G.F., Montenegro F.L.M., Machado D.J., et al. Parathyroidectomy after kidney transplantation: short- and long-term impact on renal function. CLINICS. 2011;66(3):431–435. PMID:21552668
33. Akaberi S., Clyne N., Sterner G., et al. Temporal trends and risk factors for parathyroidectomy in the Swedish dialysis and transplant population – a nationwide, population-based study 1991–2009. BMC Nephrol. 2014;15:75–81. PMID:24886448PMCI DOI:10.1186/1471-2369-15-75
34. Dewberry L.K., Weber C., Sharma J. Near total parathyroidectomyn is effective therapy for tertiary hyperparathyroidism. Am Surg. 2014;80(7):646–651. PMID:24987894
35. Messa P., Regalia A., Alfieri C.M., et al. Current indications to parathyroidectomy in CKD patients before and after transplantation. J Nephrol. 2013;26(6):1025–1032. PMID:24284524 DOI:10.5301/jn.5000277
36. Torregrosa J.V., Barros X. Management of hypercalcemia after renal transplantation. Nefrologia. 2013;33(6):751–757. PMID:24241361 DOI:10.3265/Nefrologia.pre2013.Aug.11888
37. Yang R.L., Freeman K., Reinke C.E., et al. Tertiary Hyperparathyroidism in kidney transplant recipients: Characteristics of patients selected for different treatment strategies. Transplantation. 2012;94(1):70–76. PMID:22706321 DOI:10.1097/TP.0b013e3182530699
38. Martin T.J. Osteoblast-derived PTHrP is a physiological regulator of bone formation. J Clin Invest. 2005;115(9):2322– 2324. PMID:16138187 PMC1193889 DOI:10.1172/JCI26239
39. Hsieh T.M., Sun C.K., Chen Y.T., Chou F.F. Total parathyroidectomy versus subtotal parathyroidectomy in the treatment of tertiary hyperparathyroidism. Am Surg. 2012;78(5):600–606. PMID:22546135
40. Miao D., He B., Jiang Y., et al. Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest. 2005;115(9):2402–2411. PMID:16138191 PMCID:PMC1193882 DOI:10.1172/JCI24918
41. Sadideen H.M., Taylor J.D., Goldsmith D.J. Total parathyroidectomy without autotransplantation after renal transplantation for tertiary hyperparathyroidism: long-term follow-up. Int Urol Nephrol. 2012;44(1):275–281. PMID:21997202 DOI:10.1007/s11255-011-0069-9
42. Schlosser K., Rothmund M., Maschuw K., et al. Graft-dependent Renal Hyperparathyroidism Despite Successful Kidney Transplantation. World J Surg. 2008;32(4):557–565. PMID:18204949 DOI:10.1007/s00268-007-9337-3
43. Pitt S.C., Panneerselvan R., Chen H., Sippel R.S. Secondary and Tertiary Hyperparathyroidism: The Utility of ioPTH Monitoring. World J Surg. 2010;34(6):1343– 1349. PMID:20386902 PMCID:PMC2905743 DOI:10.1007/s00268-010-0575-4
44. Nogueira E.L., Costa A.C., Santana A., et al. Teriparatide efficacy in the treatment of severe hypocalcemia after kidney transplantation in parathyroidectomized patients: a series of five case reports. Transplantation. 2011;92(3):316–320. PMID:21694663 DOI:10.1097/TP.0b013e3182247b98
45. Schwarz A., Rustien G., Merkel S., et al. Decreased renal transplant function after parathyroidectomy. Nephrol Dial Transplant. 2007;22(2):584–591. PMID:17035377DOI:10.1093/ndt/gfl583
46. Schlosser K., Endres N., Celik I., et al. Surgical treatment of tertiary hyperparathyroidism: the choice of procedure matters! World J Surg. 2007;31(10):1947–1953. PMID:17665243 DOI:10.1007/s00268-007-9187-z
47. Kalantar-Zadeh K., Molnar M.Z., Kovesdy C.P., et al. Management Mineral and Bone Disorder after Kidney Transplantation. Curr Opin Nephrol Hypertens. 2012;21(4):389– 403. PMID: 22614626 DOI:10.1097/MNH.0b013e3283546ee0
48. Courbebaisse M., Alberti C., Colas S., et al. VITamin D supplementation in renAL transplant recipients (VITALE): a prospective, multicentre, double-blind, randomized trial of vitamin D estimating the benefit and safety of vitamin D3 treatment at a dose of 100,000 UI compared with a dose of 12,000 UI in renal transplant recipients: study protocol for a double-blind, randomized, controlled trial. Trials. 2014;15:430–443. PMID:25376735 PMCID:PMC4233037 DOI:10.1186/1745-6215-15-430
49. Amer H., Griffin M.D., Stegall M.D., et al. Oral Paricalcitol Reduces the Prevalence of Posttransplant Hyperparathyroidism: Results of an Open Label Randomized Trial. Am J Transplant. 2013;13:1576–1585. PMID:23601186 DOI:10.1002/ajt.12227
50. Gonzalez E., Rojas-Rivera J., Polanco N., et al. Effects of Oral Paricalcitol on Secondary Hyperparathyroidism and Proteinuria of Kidney Transplant Patients. Transplantation. 2013;95(7):e49–e52. PMID:23545517 DOI:10.1097/TP.0b013e3182855565
51. Pérez V., Sánchez-Escuredo A., Lauzurica R., et al. Magnetic bead-based proteomic technology to study paricalcitol effect in kidney transplant recipients. Eur J Pharmacol. 2013;709(1– 3):72–79. PMID:23567070 DOI:10.1016/j.ejphar.2013.03.040
52. Trillini M., Cortinovis M., Ruggenenti P., et al. Paricalcitol for Secondary Hyperparathyroidism in Renal Transplantation. J Am Soc Nephrol. 2015;26(5):1205– 1214. PMID:25194004 DOI:10.1681/ASN.2013111185
53. Borrego Utiel F.J., Bravo Soto J.A., Merino Pérez M.J., et al. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with se condary hyperparathyroidism. Nefrologia. 2015;35(4):363–373. PMID:26306956 DOI:10.1016/j.nefro.2015.06.018
54. Vetchinnikova O.N., Kantariya R.O. Therapeutic tactics in tertiary hyperparathyroidism after renal transplantation (review and clinical observations). Clinical Nephrology. 2014;1:55–63. (In Russian).
55. Vetchinnikova O.N., Shcherbakova E.O., Polyakova E.Yu. Cinacalcet in treatment of hyperparathyroidism in recipients of renal graft. Russian Journal of Transplantology and Artificial Organs. 2014;16(1):47–53. (In Russian). DOI:10.15825/1995-1191-2014-1-47-53
56. Thiem U., Alois Gess A., Borchhardt K. Long-Term Clinical Practice Experience with Cinacalcet for Treatment of Hypercalcemic Hyperparathyroidism after Kidney Transplantation. BioMed Research International. 2015;2015:12. ID 292654. Available at: https://www.hindawi.com/journals/bmri/2015/292654/ DOI:10.1155/2015/292654
57. Okada M., Tominaga Y., Izumi K., et al. Tertiary Hyperparathyroidism Resistant to Cinacalcet Treatment. Ther Apher Dial. 2011;15(Suppl 1):33–37. PMID:21595850 DOI:10.1111/j.1744-9987.2011.00924.x
58. Cohen J.B., Gordon C.E., Balk E.M., Francis J.M. Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients: a systematic review and meta- analysis. Transplantation. 2012;94(10):1041–1048. PMID:23069843 DOI:10.1097/TP.0b013e31826c3968
59. Evenepoel P., Cooper K., Holdaas H., et al. A Randomized Study Evalu ating Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients With Persistent Hyperparathyroidism. Am J Transplant. 2014;14(11):2545–2555. PMID:25225081 DOI:10.1111/ajt.12911
Review
For citations:
Vetchinnikova O.N. Kidney transplantation and hyperparathyroidism. Transplantologiya. The Russian Journal of Transplantation. 2017;9(2):137-152. https://doi.org/10.23873/2074-0506-2017-9-2-137-152
Views:
1020
Email this article 